All stock lists
Tg Therapeutics, Inc. (NASDAQ:TGTX)
US · Delayed Price · Currency is USD
54.55+0.38 (+0.70%)
Insider Score
––Not scored
TGTX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
TGTX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 240.34 M | 204.92 M | 192.57 M | 161.71 M | 141.15 M | 120.86 M |
| Revenue Growth (YoY) | 70.27 % | 69.56 % | 78.00 % | 92.79 % | 92.13 % | 90.40 % |
| Cost of Revenue | 41.19 M | 33.51 M | 38.14 M | 28.16 M | 18.94 M | 15.54 M |
| Gross Profit | 199.14 M | 171.41 M | 154.43 M | 133.55 M | 122.21 M | 105.31 M |
| SG&A Expense | 82.13 M | 88.22 M | 62.74 M | 63.31 M | 55.59 M | 50.33 M |
| R&D Expense | 95.34 M | 48.40 M | 41.19 M | 40.88 M | 31.78 M | 46.36 M |
| Operating Expenses | 177.47 M | 136.61 M | 103.94 M | 104.19 M | 87.37 M | 96.69 M |
| Operating Income | 21.67 M | 34.80 M | 50.49 M | 29.36 M | 34.84 M | 8.62 M |
| Pretax Income | 10.23 M | 20.36 M | 45.09 M | 25.91 M | 30.92 M | 5.47 M |
| Tax Provision | 2.45 M | 586.00 K | 22.06 M | -364.99 M | 2.73 M | 408.00 K |
| Net Income | 7.78 M | 19.78 M | 23.04 M | 390.89 M | 28.19 M | 5.06 M |
| EPS (Basic) | 0.05 | 0.14 | 0.16 | 2.69 | 0.19 | 0.03 |
| EPS (Diluted) | 0.05 | 0.12 | 0.14 | 2.43 | 0.17 | 0.03 |
| Shares Outstanding | 141.77 M | 144.44 M | 142.96 M | 145.42 M | 146.74 M | 146.68 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.